Chris Ryan

Articles

Novel PET imaging agent 18F-rhPSMA-7.3 increases upstaging in recurrent prostate cancer

May 14, 2022

Compared with baseline conventional imaging, PET imaging with 18F-rhPSMA-7.3 frequently led to post-scan disease upstaging in men with prostate cancer recurrence, according to the latest data from the phase 3 SPOTLIGHT trial.